Melatonin: Nörodejeneratif Metabolik Bozukluklar ve Kanser Üzerindeki Potansiyel Etkileri

Lerner AB, Case JD, Takahashi Y. Isolation of melatonin, a pineal factor that lightens melanocytes. J Am Soc. 1958;80:2587.

Fanjul-Moles ML, López-Riquelme GO. Relationship between oxidative stress, circadian rhythms, and AMD. Oxid Med Cell Longev. 2016;2016:7420637.

Hacışevki A., Baba B. (2018). An Overview of melatonin as an antioxidant molecule: a biochemical approach. Dragoi CM, Nicolae AC (Eds). Melatonin - Molecular Biology, Clinical and Pharmaceutical Approaches (pp59-85). London: IntechOpen

Anwar MJ, Muhammad BY, Bader AA, et al. An insight into the scientific background and future perspectives for the potential uses of melatonin. Egypt. J. Basic Appl. Sci. 2015;2:139-152.

García JJ, López-Pingarrón L, Almeida-Souza P, et al. Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. J. Pineal Res. 2014;56(3):225–237.

Konturek SJ, Konturek PC, Brzozowska I, et al. Localization and biological activities of melatonin in intact and diseased gastrointestinal tract (GIT). J Physiol Pharmacol. 2007;58(3):381-405.

Kostoglou-Athanassiou I. Therapeutic applications of melatonin. Ther Adv Endocrinol Metab. 2013;4(1):13-24.

Tordjman S, Chokron S, Delorme R, et al. Melatonin: Pharmacology, Functions and Therapeutic Benefits. Curr Neuropharmacol. 2017;15(3):434-443.

Zawilska JB, Skene DJ, Arendt J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep. 2009;61(3):383-410.

Hardeland R, Cardinali DP, Srinivasan V, et al. Melatonin—A pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93(3):350-84.

Cipolla-Neto J, Amaral FG, Afeche SC, et al. Melatonin, energy metabolism, and obesity: a review. J Pineal Res. 2014;56(4):371-81.

Cardinali DP, Vigo DE, Olivar N, et al. Melatonin therapy in patients with Alzheimer’s Disease. Antioxidants. 2014;3(2):245-77.

Johns JR, Platts JA. Theoretical insight into the antioxidant properties of melatonin and derivatives. Org Biomol Chem. 2014;12(39):7820-7.

Bisquert R, Muñiz-Calvo S, Guillamón JM. Protective role of intracellular melatonin against oxidative stress and UV radiation in Saccharomyces cerevisiae. Front Microbiol. 2018;9(318):1-11.

Irvine GB, El-Agnaf OM, Shankar GM, et al. Protein aggregation in the brain: the molecular basis for Alzheimer’s and Parkinson’s diseases. Mol Med. 2008;14(7-8):451-64.

Srinivasan V, Pandi-Perumal SR, Cardinali DP, et al. Melatonin in Alzheimer’s disease and other neurodegenerative disorders. Behav Brain Funct. 2006;2:15:1-23.

Srinivasana V, Lauterbachb EC, Ahmed AH, et al. Alzheimer’s Disease Focus on the Neuroprotective Role of Melatonin. J Neurol Res 2012;2(3):69-81.

Alghamdi BS. The neuroprotective role of melatonin in neurological disorders. J Neurosci Res. 2018;96(7):1136-1149.

Choi SH, Kim YH, Hebisch M, et al. A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature. 2014;515(7526):274-8.

Ittner LM, Götz J. Amyloid-beta and tau–a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci. 2011;12(2):65-72.

Feng Y, Wang X. Antioxidant therapies for Alzheimer’s disease. Oxid Med Cell Longev. 2012;2012:472932.

Mietelska-Porowska A, Wasik U, Goras M, et al. Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci. 2014;15(3):4671-713.

Srinivasan V, Spence DW, Pandi-Perumal SR, et al. Melatonin in mitochondrial dysfunction and related disorders. Int J Alzheimers Dis. 2011;2011:326320.

Srinivasan V, Cardinali DP, Srinivasan US, et al. Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection. Ther Adv Neurol Disord. 2011;4(5):297-317.

Morton AJ. Circadian and sleep disorder in Huntington’s disease. Exp Neurol. 2013;243:34-44.

Schulte J, Littleton JT. The biological function of the Huntingtin protein and its relevance to Huntington’s Disease pathology. Curr Trends Neurol. 2011;5:65-78.

Kim S, Kim KT. Therapeutic approaches for inhibition of protein aggregation in Huntington’s disease. Exp Neurobiol. 2014;23(1):36-44.

Pandi-Perumal SR, Srinivasan V, Maestroni GJ, et al. Melatonin: Nature’s most versatile biological signal? FEBS J. 2006;273(13):2813-38.

Polimeni G, Esposito E, Bevelacqua V, et al. Role of melatonin supplementation in neurodegenerative disorders. Front Biosci. 2014;19:429-46.

Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol. 2010;8(3):228-42.

Bonnefont-Rousselot D, Collin F. Melatonin: Action as antioxidant and potential applications in human disease and aging. Toxicology. 2010;278(1):55-67.

Hardeland R. Neuroprotection by radical avoidance: search for suitable agents. Molecules.2009;14(12):5054-102.

Matsubara E, Bryant-Thomas T, Pacheco Quinto J, et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. J. Neurochem. 2003;85:1101–1108.

Chauhan V, Chauhan A. Oxidative stress in Alzheimer’s disease. Pathophysiology. 2006;13(3):19208.

Wang JZ, Wang ZF. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin. 2006;27(1):41-9.

Moneim AE. Oxidant/Antioxidant imbalance and the risk of Alzheimer’s disease. Curr Alzheimer Res. 2015;12(4):335-49.

Hossain MF, Uddin MS, Uddin GMS, et al. Melatonin in Alzheimer’s Disease: a latent endogenous regulator of neurogenesis to mitigate Alzheimer’s neuropathology. Mol Neurobiol. 2019;56(12):8255-8276.

Shukla M, Govitrapong P, Boontem P, et al. Mechanisms of melatonin in alleviating Alzheimer’s Disease. Curr Neuropharmacol. 2017;15(7):1010-1031.

Zhou J, Zhang S, Zhao X, et al. Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-beta1-42. J Pineal Res. 2008;45(2):157-65.

Liu SJ, Wang JZ. Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sin. 2002;23(2):183-7.

Ali T, Kim MO. Melatonin ameliorates amyloid beta-induced memory deficits, tau hyperphosphorylation and neurodegeneration via PI3/Akt/GSk3β pathway in the mouse hippocampus. J Pineal Res. 2015;59(1):47-59.

Lin L, Huang QX, Yang SS, et al. Melatonin in Alzheimer’s Disease. Int J Mol Sci 2013;14(7):1457514593.

Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer’s disease. J Pineal Res. 2005;38(3):145-52.

Wu YH, Feenstra MG, Zhou JN, et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab. 2003;88(12):5898-906.

Hardeland R. Melatonin in aging and disease-multiple consequences of reduced secretion, options and limits of treatment. Aging Dis. 2012;3(2):194-225.

Patki G, Lau YS. Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson’s disease. Pharmacol Biochem Behav. 2011;99(4):704-11.

Tamtaji OR, Reiter RJ, Alipoor R, et al. Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms. Cell Mol Neurobiol. 2020;40(1):15-23.

Saravanan KS, Sindhu KM, Mohanakumar KP. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J Pineal Res. 2007;42(3):247-53.

Sharma R, McMillan CR, Tenn CC, et al. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson’s disease. Brain Res. 2006;1068(1):230-6.

Capitelli C, Sereniki A, Lima MM, et al. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. Eur J Pharmacol. 2008;594(1-3):101-8.

Ma J, Shaw VE, Mitrofanis J. Does melatonin help save dopaminergic cells in MPTP-treated mice? Parkinsonism Relat Disord. 2009;15(4):307-14.

Morgan WW, Nelson JF. Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. Brain Res. 2001;921(1-2):115-21.

van der Schyf CJ, Castagnoli K, Palmer S, et al. Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum. Neurotox Res. 2000;1(4):261-9.

Kalliolia E, Silajdžić E, Nambron R, et al. Plasma melatonin is reduced in Huntington’s disease. Mov Disord. 2014;29(12):1511-5.

Bartlett DM, Cruickshank TM, Hannan AJ, et al. Neuroendocrine and neurotrophic signaling in Huntington’s disease: Implications for pathogenic mechanisms and treatment strategies. Neurosci Biobehav Rev. 2016;71:444-454.

Aziz NA, Pijl H, Frölich M, et al. Delayed onset of the diurnal melatonin rise in patients with Huntington’s disease. J Neurol 2009;256:1961–1965.

Gil-Mohapel J, Brocardo PS, Christie BR. The role of oxidative stress in Huntington’s disease: are antioxidants good therapeutic candidates? Curr Drug Targets. 2014;15(4):454-68.

Stack EC, Matson WR, Ferrante RJ. Evidence of oxidant damage in Huntington’s disease: translational strategies using antioxidants. Ann N Y Acad Sci. 2008;1147:79-92.

Túnez I, Montilla P, Del Carmen Muñoz M, et al. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington’s disease. J Pineal Res. 2004;37(4):252-6.

Zhong J, Liu Y. Melatonin and age-related cardiovascular diseases. Aging Med (Milton). 2018;1(2):197-203.

Hacışevki A, Torun M, Çengel A. Effect of short-term alfa-tocopherol supplementation on biomarkers of oxidative stress and antioxidant defence in subjects with angina pectoris. Oxidation Communication. 2012;35(1):128-137.

Dominguez-Rodriguez A. Melatonin in cardiovascular disease. Expert Opinion on Investigational Drugs. 2012;21(11):1593-1596.

Simko F, Reiter RJ, Paulis L. Melatonin as a rational alternative in the conservative treatment of resistant hypertension. Hypertens Res. 2019;42(11):1828-1831.

Baltatu OC, Amaral FG, Campos LA, et al. Melatonin, mitochondria and hypertension. Cell Mol Life Sci. 2017;74(21):3955-3964.

Halladin NL. Oxidative and inflammatory biomarkers of ischemia and reperfusion injuries. Dan Med J. 2015;62(4):B5054.

Gönenç A, Hacışevki A, Griffiths HR, Torun M, Bakkaloğlu B, Şimşek B. Free radical reaction products and antioxidant capacity in beating heart coronary artery surgery compared to conventional bypass. Biochemistry (Moscow). 2011;76(6):677-685.

Ma S, Dong Z. Melatonin attenuates cardiac reperfusion stress by improving OPA1-related mitochondrial fusion in a Yap-Hippo pathway-dependent manner. J Cardiovasc Pharmacol. 2019;73(1):27-39.

Lochner A, Marais E, Huisamen B. Melatonin and cardioprotection against ischaemia/reperfusion injury: What’s new? A review. J Pineal Res. 2018;65(1):e12490.

Yu XH, Zheng XL, Tang CK. Nuclear Factor-κB Activation as a pathological mechanism of lipid metabolism and atherosclerosis. Adv Clin Chem. 2015;70:1-30.

Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Melatonin and cardiovascular disease: myth or reality? Rev Esp Cardiol (Engl Ed). 2012;65(3):215-8.

Baltatu OC, Senar S, Campos LA, et al. Cardioprotective melatonin: translating from proof-of-concept studies to therapeutic use. Int J Mol Sci. 2019;20(18):1-19.

Hu ZP, Fang XL, Fang N, et al. Melatonin ameliorates vascular endothelial dysfunction, inflammation, and atherosclerosis by suppressing the TLR4/NF-κB system in high-fat-fed rabbits. J Pineal Res. 2013;55(4):388-98.

Prado NJ, Ferder L, Manucha W, et al. Anti-inflammatory effects of melatonin in obesity and hypertension. Curr Hypertens Rep. 2018;20(5):45.

Pechanova O, Paulis L, Simko F. Peripheral and central effects of melatonin on blood pressure regulation. Int J Mol Sci. 2014;15(10):17920-37.

Markus RP, Cecon E, Pires-Lapa MA. Immune-pineal axis: nuclear factor κB (NF-kB) mediates the shift in the melatonin source from pinealocytes to immune competent cells. Int J Mol Sci. 2013;14(6):10979-97.

Veneroso C, Tuñón MJ, González-Gallego J, et al. Melatonin reduces cardiac inflammatory injury induced by acute exercise. J Pineal Res. 2009;47(2):184-91.

Şehirli AÖ, Koyun D, Tetik Ş, et al. Melatonin protects against ischemic heart failure in rats. J Pineal Res. 2013;55(2):138-48.

Nduhirabandi F, Maarman GJ. Melatonin in heart failure: a promising therapeutic strategy? Molecules. 2018;23(7):1819.

Hung MW, Kravtsov GM, Lau CF, et al. Melatonin ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in rats with chronic intermittent hypoxia. J Pineal Res. 2013;55(3):247-56.

Benova T, Viczenczova C, Radosinska J, et al. Melatonin attenuates hypertension-related proarrhythmic myocardial maladaptation of connexin-43 and propensity of the heart to lethal arrhythmias. Can J Physiol Pharmacol. 2013;91(8):633-9.

Giacomo CG, Antonio M. Melatonin in cardiac ischemia/reperfusion-induced mitochondrial adaptive changes. Cardiovasc Hematol Disord Drug Targets. 2007;7(3):163-9.

Yang JB, Kang YM, Zhang C, et al. Infusion of melatonin into the paraventricular nucleus ameliorates myocardial ischemia-reperfusion injury by regulating oxidative stress and inflammatory cytokines. J Cardiovasc Pharmacol. 2019;74(4):336-347.

Favero G, Rodella LF, Reiter RJ, et al. Melatonin and its atheroprotective effects: a review. Mol Cell Endocrinol. 2014;382(2):926-37.

Broncel M, Kozirog-Kolacinska M, Chojnowska-Jezierska J. Melatonin in the treatment of atherosclerosis. Pol Merkur Lekarski 2007; 23:124–127.

Reiter RJ, Tan DX, Paredes SD, et al. Beneficial effects of melatonin in cardiovascular disease. Ann Med. 2010;42(4):276-85.

Sun H, Gusdon AM, Qu S. Effects of melatonin on cardiovascular diseases: progress in the past year. Curr Opin Lipidol. 2016;27(4):408-13.

Yang Y, Duan W, Jin Z, et al. JAK2/STAT3 activation by melatonin attenuates the mitochondrial oxidative damage induced by myocardial ischemia/reperfusion injury. J Pineal Res. 2013;55(3):275-86.

Lan H, Su Y, Liu Y, et al. Melatonin protects circulatory death heart from ischemia/reperfusion injury via the JAK2/STAT3 signalling pathway. Life Sci. 2019;228:35-46.

Ma S, Chen J, Feng J, et al. Melatonin ameliorates the progression of atherosclerosis via mitophagy activation and NLRP3 inflammasome inhibition. Oxid Med Cell Longev. 2018;2018:9286458.

Tuomi T, Nagorny CLF, Singh P, et al. Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metab. 2016;23(6):1067-1077.

Burgos-Morón E, Abad-Jiménez Z, Marañón AM, et al. Relationship between oxidative stress, ER stress, and inflammation in Type 2 diabetes: The battle continues. J Clin Med. 2019;8(9):1385.

Zephy D, Ahmad J. Type 2 diabetes mellitus: Role of melatonin and oxidative stress. Diabetes Metab Syndr. 2015;9(2):127-31.

Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian J Endocrinol Metab. 2016;20(4):546-51.

Espino J, Pariente JA, Rodríguez AB. Role of melatonin on diabetes-related metabolic disorders. World J Diabetes. 2011;2(6):82-91.

Mulder H. Melatonin signalling and type 2 diabetes risk: too little, too much or just right? Diabetologia. 2017;60(5):826-829.

Forrestel AC, Miedlich SU, Yurcheshen M, et al. Chronomedicine and type 2 diabetes: shining some light on melatonin. Diabetologia. 2017;60(5):808-822.

Peschke E. Melatonin, endocrine pancreas and diabetes. J Pineal Res. 2008;44(1):26-40.

Sharma S, Singh H, Ahmad N, et al. The role of melatonin in diabetes: therapeutic implications. Arch Endocrinol Metab. 2015;59(5):391-9.

Costes S, Boss M, Thomas AP, et al. Activation of melatonin signaling promotes β-cell survival and function. Mol Endocrinol. 2015;29(5):682-92.

Lyssenko V, Nagorny CL, Erdos MR, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82-8.

Müssig K, Staiger H, Machicao F, et al. Genetic variants in MTNR1B affecting insulin secretion. Ann Med. 2010;42:387–393.

Karamitri A, Jockers R. Melatonin in type 2 diabetes mellitus and obesity. Nat Rev Endocrinol. 2019;15(2):105-125.

Mok JX, Ooi JH, Ng KY, et al. A new prospective on the role of melatonin in diabetes and its complications. Horm Mol Biol Clin Investig. 2019 Nov 6; 40(1):/j/hmbci.2019.40.issue-1/hmbci-2019-0036/hmbci-2019-0036.xml. doi: 10.1515/hmbci-2019-0036.

McMullan CJ, Schernhammer ES, Rimm EB, et al. Melatonin secretion and the incidence of type 2 diabetes. JAMA. 2013;309(13):1388-96.

Kedziora-Kornatowska K, Szewczyk-Golec K, Kozakiewicz M, et al. Melatonin improves oxidative stress parameters measured in the blood of elderly type 2 diabetic patients. J Pineal Res. 2009;46(3):333-7.

Lopes de Faria JB, Silva KC, Lopes de Faria JM. The contribution of hypertension to diabetic nephropathy and retinopathy: the role of inflammation and oxidative stress. Hypertens Res. 2011;34(4):413-22.

Cecilia OM, José Alberto CG, José NP, et al. Oxidative stress as the main target in diabetic retinopathy pathophysiology. J Diabetes Res. 2019;2019:8562408.

Onk D, Onk OA, Turkmen K, et al. Melatonin attenuates contrast-induced nephropathy in diabetic rats: the role of interleukin-33 and oxidative stress. Mediators Inflamm. 2016;2016:9050828.

Dehdashtian E, Mehrzadi S, Yousefi B, et al. Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. Life Sci. 2018;193:20-33.

Jiang T, Chang Q, Cai J, et al. Protective effects of melatonin on retinal inflammation and oxidative stress in experimental diabetic retinopathy. Oxid Med Cell Longev. 2016;2016(3528274):113.

Mehrzadi S, Motevalian M, Rezaei Kanavi M, et al. Protective effect of melatonin in the diabetic rat retina. Fundam Clin Pharmacol. 2018;32(4):414-421.

Elbe H, Vardi N, Esrefoglu M, et al. Amelioration of streptozotocin-induced diabetic nephropathy by melatonin, quercetin, and resveratrol in rats. Hum Exp Toxicol. 2015;34(1):100-13.

Ebaid H, Bashandy SAE, Abdel-Mageed AM, et al. Folic acid and melatonin mitigate diabetic nephropathy in rats via inhibition of oxidative stress. Nutr Metab (Lond). 2020;17:6.

Winiarska K, Dzik JM, Labudda M, et al. Melatonin nephroprotective action in Zucker diabetic fatty rats involves its inhibitory effect on NADPH oxidase. J Pineal Res. 2016;60(1):109-17.

Negi G, Kumar A, Sharma SS. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-κB and Nrf2 cascades. J Pineal Res. 2011;50(2):124-31.

Metwally MMM, Ebraheim LLM, Galal AAA. Potential therapeutic role of melatonin on STZ-induced diabetic central neuropathy: A biochemical, histopathological, immunohistochemical and ultrastructural study. Acta Histochem. 2018;120(8):828-836.

Chen W, Cao H, Lu QY, et al. Urinary 6-sulfatoxymelatonin level in diabetic retinopathy patients with type 2 diabetes. Int J Clin Exp Pathol. 2014;7(7):4317-22.

Hacışevki A, Baba B, Gönenç A, et al. Protein carbonyl content as the most general and well-used biomarker of severe oxidative stress, Oxid. Commun. 2012;35(2):413-422.

Hacışevki A, Baba B, Aslan S, et al. Neopterin: A possible biomarker in gastrointestinal cancer. J. Fac. Pharm. Ankara, 2018;42(2):32-41.

Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harb Perspect Med. 2015;5(4):a006098.

Sánchez A, Calpena AC, Clares B. Evaluating the oxidative stress in ınflammation: role of melatonin. Int J Mol Sci. 2015;16(8):16981-7004.

Asghari MH, Moloudizargari M, Ghobadi E, et al. Melatonin as a multifunctional anti-cancer molecule: Implications in gastric cancer. Life Sciences 2017;185:38–45.

Reiter RJ, Rosales-Corral SA, Tan DX, et al. Melatonin, a full service anti-cancer agent: Inhibition of initiation, progression and metastasis. Int J Mol Sci. 2017;18(4):843.

Talib WH. Melatonin and cancer hallmarks. Molecules. 2018;23(3):518.

Hill SM, Belancio VP, Dauchy RT, et al. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer. 2015;22(3):R183-204.

Farhood B, Goradel NH, Mortezaee K, et al. Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment. J Cell Physiol. 2019;234(5):5613-5627.

Mohan, N. Sadeghi, K. Reiter, R.J. et al. The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B. Biochem. Mol. Biol. Int. 1995;37:1063–1070.

Zare H, Shafabakhsh R, Reiter RJ, et al. Melatonin is a potential inhibitor of ovarian cancer: molecular aspects. J Ovarian Res. 2019;12(1):26.

Khan KH, Yap TA, Yan L, et al. Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer. 2013;32(5):253-65.

Wang J, Xiao X, Zhang Y, et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res. 2012;53(1):77-90.

Ferreira GM, Martinez M, Camargo IC, et al. Melatonin attenuates Her-2, p38 MAPK, p-AKT, and mTOR levels in ovarian carcinoma of ethanol-preferring rats. J Cancer. 2014;5(9):728-35.

Goradel NH, Asghari MH, Moloudizargari M, et al. Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence. Toxicol Appl Pharmacol. 2017;335:56-63.

Carbajo-Pescador S, Ordoñez R, Benet M, et al. Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer. 2013;109(1):83-91.

Su SC, Hsieh MJ, Yang WE, Chung WH, Reiter RJ, Yang SF. Cancer metastasis: Mechanisms of inhibition by melatonin. J Pineal Res. 2017;62(1):1-11.

Jaworek J, Leja-Szpak A. Melatonin influences pancreatic cancerogenesis. Histol Histopathol. 2014;29(4):423-31.

Leja-Szpak A, Jaworek J, Pierzchalski P, et al. Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res. 2010;49(3):248-55.

Li W, Wu J, Li Z, et al. Melatonin induces cell apoptosis in Mia PaCa-2 cells via the suppression of nuclear factor-κB and activation of ERK and JNK: A novel therapeutic implication for pancreatic cancer. Oncol Rep. 2016;36(5):2861-2867.

Jaworek J, Leja-Szpak A, Nawrot-Porąbka K, et al. Effects of melatonin and its analogues on pancreatic inflammation, enzyme secretion, and tumorigenesis. Int J Mol Sci. 2017;18(5):1014.

Song J, Ma SJ, Luo JH, et al. Melatonin induces the apoptosis and inhibits the proliferation of human gastric cancer cells via blockade of the AKT/MDM2 pathway. Oncol Rep. 2018;39(4):1975-1983.

Mortezaee K. Human hepatocellular carcinoma: Protection by melatonin. J Cell Physiol, 2018;233(10):6486-6508.

Wang TH, Hsueh C, Chen CC, et al. Melatonin inhibits the progression of hepatocellular carcinoma through microRNA Let7i-3p mediated RAF1 reduction. Int J Mol Sci. 2018;19(9):2687.

Hong Y, Won J, Lee Y, et al. Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells. J Pineal Res. 2014;56(3):264-74.

Yun CW, Kim S, Lee JH, et al. Melatonin promotes apoptosis of colorectal cancer cells via superoxide-mediated ER stress by inhibiting cellular prion protein expression. Anticancer Res. 2018;38(7):3951-3960.

Yang YC, Chiou PC, Chen PC, et al. Melatonin reduces lung cancer stemness through inhibiting of PLC, ERK, p38, β-catenin, and Twist pathways. Environ Toxicol. 2019;34(2):203-209.

Fan C, Pan Y, Yang Y, et al. HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways. J Pineal Res. 2015;59:321-333.

Liu VWS, Yau WL, Tam CW, et al. Melatonin inhibits androgen receptor splice variant-7 (AR-V7)-induced nuclear factor-kappa B (NF-κB) activation and NF-κB activator-induced AR-V7 expression in prostate cancer cells: Potential implications for the use of melatonin in castration-resistant prostate cancer (CRPC) Therapy. Int J Mol Sci. 2017;18(6):1130.

Joo SS, Yoo YM. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res. 2009;47:8-14.

González-González A, Mediavilla MD, Sánchez-Barceló EJ. Melatonin: A molecule for reducing breast cancer risk. Molecules. 2018;23(2):336.

Hill SM, Blask DE, Xiang S, et al. Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. J Mammary Gland Biol Neoplasia. 2011;16(3):235-45.

Alvarez-García V, González A, Alonso-González C, et al. Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J Pineal Res. 2013;54:373–380.

Alonso-González C, Menéndez-Menéndez J, González-González A, et al. Melatonin enhances the apoptotic effects and modulates the changes in gene expression induced by docetaxel in MCF-7 human breast cancer cells. Int J Oncol. 2018;52(2):560-570.

Mocková K, Mníchová M, Kubatka P, et al. Mammary carcinogenesis induced in Wistar:han rats by the combination of ionizing radiation and dimethylbenz(a)anthracene: prevention with melatonin. Neoplasma. 2000;47(4):227-9.

Anisimov VN, Popovich IG, Zabezhinski MA. Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis. 1997;18(8):1549-53.

Uguz AC, Cig B, Espino J, et al. Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells. J Pineal Res. 2012;53(1):91-8